Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
Byoung Chul Cho(Yonsei University), Patricia Lorenzini(Harbin Medical University), Dawn Millington(Harbin Medical University), Michael J. Thomas(Harbin Medical University), Shun Lu(Ningbo University), Jorge Alatorre-Alexander, Melissa Martínez(Carilion Clinic), Benjamin Besse(Institut Gustave Roussy), Shirish M. Gadgeel(Chinese University of Hong Kong), Raffaele Califano(The Christie NHS Foundation Trust), Mahesh Daksh(Harbin Medical University), Pongwut Danchaivijitr(Siriraj Hospital), M. D’Arcangelo(Harbin Medical University), Baogang Liu(Harbin Medical University), Antonio Passaro(European Institute of Oncology), Hiroshige Yoshioka(Harbin Medical University), Marina Peregudova(Harbin Medical University), E. Fennema(Harbin Medical University), Juan Carlos Vázquez Limón(Harbin Medical University), Alexander I. Spira(Virginia Cancer Specialists), Sang‐We Kim(Ulsan College), Mehmet Alı Nahıt Şendur(Ankara Yıldırım Beyazıt University), Isabelle Leconte(Actelion (Switzerland)), Danny Nguyen(Harbin Medical University), James Chih‐Hsin Yang(National Taiwan University Hospital), Ying Cheng(Jilin Province Tumor Hospital), Josiane Mourão Dias(Harbin Medical University), Tao Sun(Wuhan University), Sara Alves(Harbin Medical University), Daniil Stroyakovskiy(Shikoku Cancer Center), Gee‐Chen Chang(National Yang Ming Chiao Tung University), Ryota Iwasawa(Imperial College London), Yurii Ostapenko(Harbin Medical University), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Ozan Yazıcı(Harbin Medical University), Sanjay Mukhedkar(Harbin Medical University), Enriqueta Felip(Institut Català d'Ornitologia), Nicolas Girard(Institut Curie), Hailin Xiong(Harbin Medical University), Ki-Hyeong Lee(Harbin Medical University), John Xie(Harbin Medical University), Ernesto Korbenfeld(Harbin Medical University), Soon-Hin How(Harbin Medical University), Kumar Prabhash(Harbin Medical University), Mariah Ennis(Harbin Medical University), Vanesa Gutiérrez Calderón(Harbin Medical University), Jong-Seok Lee(Harbin Medical University), Filippo de Marinis(Carlo Forlanini Hospital), Se-Hoon Lee(Harbin Medical University), Adlinda Alip(Harbin Medical University)
Cited by 369
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k